戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 erently from vinblastine, a first generation Vinca alkaloid.
2 grafted tumors as effectively as taxanes and vinca alkaloids.
3 rarely has been applied to studies involving vinca alkaloids.
4 umor activities of the two second-generation Vinca alkaloids.
5 e efficacy of paclitaxel, docetaxel, and the vinca alkaloids.
6 , including platinum compounds, taxanes, and vinca alkaloids.
7 nding of paclitaxel and increased binding of Vinca alkaloids.
8 y to paclitaxel and decreased sensitivity to vinca alkaloids.
9 s using anthracyclines, glucocorticoids, and Vinca alkaloids.
10 r 6 mutants were cross-resistant only to the Vinca alkaloids.
11 ivative, vinorelbine (Navelbine), with other vinca alkaloids.
12 f the energetics of spiral formation for two vinca alkaloids: a novel difluorinated vinorelbine deriv
13 e binding site on tubulin differing from the vinca alkaloid and dolastatin 10 binding sites, or that
14  the massive stable structures observed with vinca alkaloids and antimitotic peptides.
15 with Dx5, with decreased cross-resistance to Vinca alkaloids and no resistance to dactinomycin.
16 ive inhibition of the tubulin binding of the Vinca alkaloids and other antimitotic agents, (2) proxim
17                                   Hybrids of vinca alkaloids and phomopsin A have been elaborated wit
18 ent antimitotic cancer chemotherapy based on vinca alkaloids and taxanes target tubulin, a protein re
19                   Some of the drugs, such as Vinca alkaloids and taxol, are routinely used for cancer
20 hat vinpocetine, a synthetic derivative of a vinca alkaloid, and hardwickiic acid, a natural product
21 ubulin that is distinct from the colchicine, vinca alkaloid, and paclitaxel binding sites and some, i
22 nclude liposomal anthracyclines, paclitaxel, vinca alkaloids, and bleomycin.
23 ance to anthracyclines, epipodophyllotoxins, vinca alkaloids, and some alkylating agents.
24 e to killing by MDR-sensitive drugs, such as vinca alkaloids, anthracyclines, podophyllins, and pacli
25                                              Vinca alkaloids appear to inhibit cell proliferation by
26                                  Taxanes and Vinca alkaloids are among the most active classes of dru
27                                              Vinca alkaloids are antimitotic drugs that inhibit micro
28                                              Vinca alkaloids are antineoplastic agents that halt cell
29                                  Taxanes and vinca alkaloids are in widespread use and have demonstra
30  residues that are crucial to the binding of vinca alkaloids are shown to be strongly involved in lon
31 775), KSP (ispinesib), and tubulin (taxanes, vinca alkaloids), are presented.
32 geting agents (MTA), such as the taxanes and vinca alkaloids, are used to treat a variety of cancers
33                       AB-5, like taxanes and vinca alkaloids, blocks cell division during mitosis.
34 often used in combination with bleomycin and vinca alkaloids, can lead to vascular events including a
35  the shortest (five-step) total synthesis of vinca alkaloid catharanthine to date, proceeding via its
36  agents in clinical use, the taxanes and the vinca alkaloids, come from terrestrial sources, the sea
37     The ability of a class of C-20' modified vinca alkaloid congeners to induce tubulin spiral format
38 e studies comparing the interaction of a new vinca alkaloid derivative, vinorelbine (Navelbine), with
39 ategy has allowed fast access to a family of vinca alkaloid derivatives with an enlarged and function
40 tafolide), a conjugate of folic acid and the vinca alkaloid desacetylvinblastine hydrazide (DAVLBH),
41 or the response of breast cancer patients to Vinca alkaloid drug treatment.
42  Because RALBP1 transports anthracycline and Vinca alkaloid drugs, as well as GS-E, and because it co
43 ide was accompanied by cell sensitization to Vinca alkaloids, gramicidin D, and Taxol with no effect
44 ne (Navelbine), an amphiphilic semisynthetic Vinca alkaloid, has displayed superior activity and decr
45 e role of single-agent vinblastine and other vinca alkaloid in the management of pediatric LGGs deser
46 active route to the tetracyclic core of some vinca alkaloids, including the tetrahydroisoquinocarbazo
47             Cross-resistance was observed to Vinca alkaloids, including vincristine, vinorelbine, and
48 superior antitumor activity to that of other Vinca alkaloids, including vinorelbine from which it was
49  nucleotides are allosteric effectors of the vinca alkaloid-induced self-association of tubulin.
50 ed by the observation that the energetics of vinca alkaloid-induced tubulin spiral polymers, or spira
51  of the initial interaction between P-gp and Vinca alkaloids occurs in the cytoplasm.
52            Whereas many drugs, including the vinca alkaloids, often become less effective when p53 is
53 y developed a new group of folate-conjugated Vinca alkaloids, one of which, EC145, emerged as a candi
54 xic agents such as liposomal anthracyclines, vinca alkaloids, or paclitaxel.
55 ntered by cancer patients receiving taxane-, vinca alkaloid- or platin-based chemotherapy.
56                        Vinflunine is a novel Vinca alkaloid presently in Phase I clinical trials.
57 ncer treatment including taxanes, platinums, vinca-alkaloids, proteasome inhibitors, and thalidomide.
58 ty (many-fold greater than paclitaxel or the vinca alkaloids) raises important questions about its me
59 otherapeutic drugs (e.g., anthracyclines and vinca alkaloids) should concentrate in acidic organelles
60                          Vinflunine, a novel vinca alkaloid, showed some activity and was recently ap
61 ults indicate that cryptophycin disrupts the Vinca alkaloid site of tubulin; however, the molecular d
62                    Drugs such as taxanes and vinca alkaloids specifically target microtubules and cau
63          Since chemical modifications of the vinca alkaloid structure are known to modulate the overa
64 ored cellular sensitivity to anthracyclines, Vinca alkaloids, taxanes, and other anticancer drugs.
65 ly with platinum- and taxane-based regimens, vinca alkaloids, thalidomide and bortezomib, and is also
66 hmin expression on the action of taxanes and Vinca alkaloids using a panel of human breast cancer cel
67 kg, intravenous methylprednisolone 30 mg/kg, Vinca alkaloids (VCR 0.03 mg/kg), and/or intravenous ant
68 o other groups of anticancer drugs including vinca alkaloids (vinblastine and vincristine) and anthra
69 ffer significantly from those of the classic Vinca alkaloid, vinblastine.
70 lls created by continuous selection with the vinca alkaloid vincristine (HL60 RV+) or by retroviral i
71 itors sodium azide/2-deoxyglucose and by the vinca alkaloid, vincristine, but not by the chemotherape
72                    The two second-generation Vinca alkaloids, vinorelbine and vinflunine, affect micr
73 eases microtubule binding and sensitivity to Vinca alkaloids, which promotes microtubule depolymeriza